This is important since we have previously only reported treatment of RMs with D1MT, a generalized IDO inhibitor, which is known to induce Th1 responses, either as a monotherapy or adjunctive to anti-TB drugs (17, 19). The gene discussed is IDO1; the disease is tuberculosis.